NCT00880308 2020-12-19
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
Clinical Trials
11 trialsNCT01208831 2020-12-19
An East Asian Study of LDE225
Novartis
Phase 1 Completed
NCT01576666 2020-12-19
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01769768 2020-12-19
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
Novartis
Phase 1 Completed
NCT01456676 2020-12-09
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
Novartis
Phase 1 Completed
NCT01787552 2020-04-15
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Novartis
Phase 1/2 Completed
NCT01327053 2019-08-28
BOLT
Novartis
Phase 2 Completed
NCT01708174 2017-08-11
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
Novartis
Phase 2 Completed
NCT01826214 2016-08-30
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
Novartis
Phase 2 Completed
NCT02002689 2016-05-02
SIGNATURE
Novartis
Phase 2 Terminated
NCT01350115 2015-10-19
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Novartis
Phase 2 Completed